Navigation Links
Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
Date:3/12/2008

tion: the company's dependence on the success of its only two product candidates; additional ongoing or planned clinical trials of Acetavance or Omigard conducted by the company may produce negative or inconclusive results, or may be inconsistent with clinical trials previously conducted by Cadence, its licensors or others; delays in completing Cadence's clinical trials or achieving its product development goals, or significant issues regarding the results, design or execution of its clinical trials; the potential need or requirement to expand or modify the company's ongoing clinical trials or to conduct additional clinical trials; the market potential for Cadence's product candidates, and its ability to compete with new or existing products; unanticipated adverse side effects or inadequate therapeutic efficacy of the company's product candidates; delays or quality issues with respect to completion of pre-commercialization manufacturing development activities; other difficulties or delays in developing, testing, manufacturing, obtaining regulatory approval for, and marketing Cadence's product candidates; the scope, validity and limitations in the company's patent rights, and its ability to maintain patent protection for its product candidates; the need to obtain substantial additional funding to complete the company's clinical development programs and successfully launch its products, and the potential that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed in Cadence's prior press releases as well as in Cadence's periodic public filings with the Securities and Exchange Commission.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after th
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
2. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
3. ISTA Pharmaceuticals to Present at the Cowen & Company 28th Annual Health Care Conference
4. SGX Pharmaceuticals Announces Fourth Quarter and Full Year Financial Results
5. Onyx Pharmaceuticals to Present at Lehman Brothers Global Healthcare Conference
6. Idenix Pharmaceuticals to Present at the Eleventh Annual Lehman Brothers Global Healthcare Conference
7. Drinking Water Association Discusses Pharmaceuticals in Water
8. Genesis Pharmaceuticals Changes Auditors
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. Vion Pharmaceuticals Regains NASDAQ Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... CA (PRWEB) , ... August 27, 2015 , ... ... plans to enter the exploding legal marijuana industry with the launch of its ... consumers of legal marijuana to order products from their smart phones and tablets. ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of ... the Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and ... State University study. , While most people don’t develop persistent depression after a ...
(Date:8/27/2015)... ... ... The Naderi Center is proud to announce that its own Dr. ... submental fat. The first and only Food and Drug Administration (FDA) approved treatment ... the only Board Certified surgeon in the D.C., Maryland, Virginia area to offer this ...
(Date:8/27/2015)... Yardley, Penn. (PRWEB) , ... August 27, 2015 ... ... engagement solutions, confirmed today that its Krames Patient Education content is ICD-10 ready ... and is ready for the new ICD-10 code sets, which are more targeted ...
(Date:8/27/2015)... ... August 27, 2015 , ... Zensah®, ... Glushko, professional Tennis player for Israel in the Women’s Tennis Association (WTA). Glushko ... her training and recovery. , With a focus on technology and comfort, Zensah® ...
Breaking Medicine News(10 mins):Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3
... cell startlingly similar to its human counterpart will likely ... organ tissue in people, two studies reported Wednesday. ... the inner-most layer of week-old rodent embryos, will provide ... diseases and injuries, the researchers said. ,"They ...
... Czech authorities said Wednesday the H5N1 virus, which is potentially lethal ... its recent discovery among wild birds in Germany. ... farm near the village of Norin, just four kilometers (2.5 miles) ... after the virus was detected there. ,The farm in ...
... the world, but the situation remains critical in Egypt and ... a major human threat remains high, the UN health ... countries in Asia, Eastern Europe and the Middle East where ... it was rapidly detected and eliminated or controlled," said Joseph ...
... Saing Ratha lies semi-conscious, her thin body shaking with fever as ... ice under her arms. ,Her 10-year-old bother Saing ... in this spartan rural clinic. ,Both have been struck ... in the first six months of this year as during the ...
... Ever dreamed of being drawn close to a smiling Marilyn ... ,A Japanese firm on Wednesday unveiled a ... of three-dimensional images using a sensor-loaded glove. ,The ... of a screen and has a glove that allows users ...
... authorities and United Nations agencies said Thursday they will immunise ... in history. ,The virulent disease is one ... the lives of 58 children a day, but vaccination coverage ... the largest immunization campaign in the world. I think it ...
Cached Medicine News:Health News:'Missing Link' Stem Cells may Shorten Path to Therapies 2Health News:'Missing Link' Stem Cells may Shorten Path to Therapies 3Health News:Potentially Lethal H5N1 Bird Flu Resurfaces in Europe 2Health News:Bird Flu Risk Still Running High in Egypt, Indonesia, WHO Says 2Health News:Dengue Deaths Sweeping Cambodia Highlight Healthcare Failures 2Health News:Dengue Deaths Sweeping Cambodia Highlight Healthcare Failures 3Health News:Pakistan to Launch World's Biggest Anti-measles Drive 2
(Date:8/26/2015)... PUNE, India , August 27, 2015 ... market research reports reviewing the genotyping technology, ... as well as single nucleotide polymorphism (SNP) ... ReportsnReports.com. Complete report on genotyping ... spread across 200 pages, profiling 10 major ...
(Date:8/26/2015)... NEW YORK , Aug. 26, 2015 ... estimated to witness a CAGR of 7.8% during the ... North American ophthalmology cataract surgery devices market in 2014 ... North American ophthalmology cataract surgery devices market is expected ... owing to the increasing strategic expansion of the companies ...
(Date:8/26/2015)... 2015 Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, today announced that it has ... privately held company and developer of a transcatheter mitral ... had signed an agreement to acquire CardiAQ. ... $350 million cash for CardiAQ at closing, with an ...
Breaking Medicine Technology:Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 3Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 5North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 2North America Ophthalmology Cataract Surgery Devices Market by Sub-Market, by End-User - Analysis and Forecast to 2019 3Edwards Lifesciences Corporation Completes Acquisition Of CardiAQ 2
Enhances the eye color of light-eyed patients....
Expressions Accents contact lenses let you enhance your eyes natural color while enjoying incredible comfort and outstanding vision quality....
Modern, innovative and quick Intense Pulsed Light system. The Flash 1 is light and very compact, thus easily portable. Available in two different colors....
... Vasculight SR improves the appearance of photo-aged ... benign brown pigments, telangiectasias, and broken capillaries. ... pulsed light (IPLTM) treats pigmentary sun damage ... combined approach of IPL and the Nd:YAG ...
Medicine Products: